U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C13H17N3O
Molecular Weight 231.2936
Optical Activity ( - )
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AL-38022A

SMILES

C[C@H](N)CN1N=CC2=C1C3=C(OCCC3)C=C2

InChI

InChIKey=FJRIVFVALIEIOY-VIFPVBQESA-N
InChI=1S/C13H17N3O/c1-9(14)8-16-13-10(7-15-16)4-5-12-11(13)3-2-6-17-12/h4-5,7,9H,2-3,6,8,14H2,1H3/t9-/m0/s1

HIDE SMILES / InChI

Molecular Formula C13H17N3O
Molecular Weight 231.2936
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

Substance Class Chemical
Created
by admin
on Sat Dec 16 17:59:10 GMT 2023
Edited
by admin
on Sat Dec 16 17:59:10 GMT 2023
Record UNII
76NY5U584E
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
AL-38022A
Code English
(2S)-1-{1H,7H,8H,9H-pyrano[2,3-g]indazol-1-yl}propan-2-amine
Systematic Name English
Pyrano[2,3-g]indazole-1(7H)-ethanamine, 8,9-dihydro-α-methyl-, (αS)-
Systematic Name English
(αS)-8,9-Dihydro-α-methylpyrano[2,3-g]indazole-1(7H)-ethanamine
Systematic Name English
(S)-(-)-2-(8,9-Dihydro-7H-pyrano[2,3-g]indazol-1-yl)-1-methylethylamine
Systematic Name English
Code System Code Type Description
EPA CompTox
DTXSID40626203
Created by admin on Sat Dec 16 17:59:10 GMT 2023 , Edited by admin on Sat Dec 16 17:59:10 GMT 2023
PRIMARY
CAS
478132-11-5
Created by admin on Sat Dec 16 17:59:10 GMT 2023 , Edited by admin on Sat Dec 16 17:59:10 GMT 2023
PRIMARY
WIKIPEDIA
AL-38022A
Created by admin on Sat Dec 16 17:59:10 GMT 2023 , Edited by admin on Sat Dec 16 17:59:10 GMT 2023
PRIMARY
FDA UNII
76NY5U584E
Created by admin on Sat Dec 16 17:59:10 GMT 2023 , Edited by admin on Sat Dec 16 17:59:10 GMT 2023
PRIMARY
PUBCHEM
22496603
Created by admin on Sat Dec 16 17:59:10 GMT 2023 , Edited by admin on Sat Dec 16 17:59:10 GMT 2023
PRIMARY
Related Record Type Details
TARGET -> AGONIST
TARGET -> AGONIST
TARGET -> AGONIST